Organon OGN Cozaar/Hyzaar — Revenue

Other product segments

Similar metrics at other companies

CSGPCoStar — Revenue

$337M+24.4%

LENOther revenues — Revenue

$331.4M-6.8%

PRGOther Revenues — Revenue

$21.62M+165%

BDLOther Revenues — Revenue

$88K+27.5%

AEPCommercial Revenues — Revenue

$1.21B+15.4%

EQIXRecurring revenues — Revenue

$2.38B+10.9%

FAQ

What is Organon's cozaar/hyzaar — revenue?

Organon (OGN) reported cozaar/hyzaar — revenue of $57M in Q1 2026.

How has Organon's cozaar/hyzaar — revenue changed year-over-year?

Organon's cozaar/hyzaar — revenue increased by 3.6% year-over-year, from $55M to $57M.

What is the long-term trend for Organon's cozaar/hyzaar — revenue?

Over 4 years (2021 to 2025), Organon's cozaar/hyzaar — revenue has grown at a -11.4% compound annual growth rate (CAGR), from $355M to $219M.

What does cozaar/hyzaar — revenue mean?

This metric represents the total net sales generated from the Cozaar and Hyzaar product line, which are established pharmaceutical therapies used for the treatment of hypertension. Tracking these revenues provides insight into the lifecycle performance and market demand for mature cardiovascular medications within the company's established brands portfolio. It serves as a key indicator of the revenue contribution and sustainability of legacy assets as they face generic competition or market saturation.